Literature DB >> 23045586

Targeting B-Cell receptor signaling for anticancer therapy: the Bruton's tyrosine kinase inhibitor ibrutinib induces impressive responses in B-cell malignancies.

Adrian Wiestner1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 23045586     DOI： 10.1200/JCO.2012.44.4281

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  49 in total

Review 1.  Bruton's tyrosine kinase inhibitors and their clinical potential in the treatment of B-cell malignancies: focus on ibrutinib.

Authors:  Amin Aalipour; Ranjana H Advani
Journal:  Ther Adv Hematol       Date:  2014-08

2.  [Chronic lymphocytic leukemia: current standards and novel approaches].

Authors:  E Tausch; S Stilgenbauer
Journal:  Internist (Berl)       Date:  2014-12       Impact factor: 0.743

Review 3.  Do mantle cell lymphomas have an 'Achilles heel'?

Authors:  Nakhle Saba; Adrian Wiestner
Journal:  Curr Opin Hematol       Date:  2014-07       Impact factor: 3.284

4.  Ibrutinib inhibits BCR and NF-κB signaling and reduces tumor proliferation in tissue-resident cells of patients with CLL.

Authors:  Sarah E M Herman; Rashida Z Mustafa; Jennifer A Gyamfi; Stefania Pittaluga; Stella Chang; Betty Chang; Mohammed Farooqui; Adrian Wiestner
Journal:  Blood       Date:  2014-03-21       Impact factor: 22.113

5.  Effect of kinase inhibitors on the therapeutic properties of monoclonal antibodies.

Authors:  Minh Ngoc Duong; Eva-Laure Matera; Doriane Mathé; Anne Evesque; Sandrine Valsesia-Wittmann; Béatrice Clémenceau; Charles Dumontet
Journal:  MAbs       Date:  2015       Impact factor: 5.857

Review 6.  Ten things you should know about protein kinases: IUPHAR Review 14.

Authors:  Doriano Fabbro; Sandra W Cowan-Jacob; Henrik Moebitz
Journal:  Br J Pharmacol       Date:  2015-03-24       Impact factor: 8.739

7.  FAS-antisense 1 lncRNA and production of soluble versus membrane Fas in B-cell lymphoma.

Authors:  L Sehgal; R Mathur; F K Braun; J F Wise; Z Berkova; S Neelapu; L W Kwak; F Samaniego
Journal:  Leukemia       Date:  2014-04-03       Impact factor: 11.528

Review 8.  Targeting the B-cell receptor signaling pathway in B lymphoid malignancies.

Authors:  Maike Buchner; Markus Müschen
Journal:  Curr Opin Hematol       Date:  2014-07       Impact factor: 3.284

9.  Targeting BTK through microRNA in chronic lymphocytic leukemia.

Authors:  Arianna Bottoni; Lara Rizzotto; Tzung-Huei Lai; Chaomei Liu; Lisa L Smith; Rose Mantel; Sean Reiff; Dalia El-Gamal; Karilyn Larkin; Amy J Johnson; Rosa Lapalombella; Amy Lehman; William Plunkett; John C Byrd; James S Blachly; Jennifer A Woyach; Deepa Sampath
Journal:  Blood       Date:  2016-10-17       Impact factor: 22.113

Review 10.  Ibrutinib: first global approval.

Authors:  Fiona Cameron; Mark Sanford
Journal:  Drugs       Date:  2014-02       Impact factor: 9.546
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.